Insulin independence after total pancreatectomy and islet autotransplant (TPIAT) for chronic pancreatitis is limited by a high rate of postprocedure beta cell apoptosis. Endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are increased by dipeptidyl peptidase 4 inhibitor therapy (sitagliptin) may protect against beta cell apoptosis. To determine the effect of sitagliptin after TPIAT, 83 adult TPIAT recipients were randomized to receive sitagliptin (n = 54) or placebo (n = 29) for 12 months after TPIAT. At 12 and 18 months after TPIAT, participants were assessed for insulin independence; metabolic testing was performed with mixed meal tolerance testing and frequent sample intravenous glucose tolerance testing. Insulin independence did not differ between the sitagliptin and placebo groups at 12 months (42% vs. 45%, p = 0.82) or 18 months (36% vs. 44%, p = 0.48). At 12 months, insulin dose was 9.0 (standard error 1.7) units/day and 7.9 (2.2) units/day in the sitagliptin and placebo groups, respectively (p = 0.67) and at 18 months 10.3 (1.9) and 7.1 (2.6) units/day, respectively (p = 0.32). Hemoglobin A 1c levels and insulin secretory measures were similar in the two groups, as were adverse events. In conclusion, sitagliptin could be safely administered but did not improve metabolic outcomes after TPIAT.
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Introduction
Total pancreatectomy with islet autotransplantation (TPIAT) may be performed for severe, chronic pancreatitis refractory to medical and endoscopic therapies (1, 2) . The goal of the islet autotransplant procedure is to preserve endogenous insulin production; however, over half of patients still require lifelong exogenous insulin following the procedure (2) (3) (4) (5) . One barrier to insulin independence after islet transplantation is the high rate of beta cell apoptosis and early beta cell loss, related to the stress of the islet isolation procedure, posttransplant islet hypoxia, innate inflammation and hyperstimulation from hyperglycemia (6) (7) (8) (9) (10) (11) . Similar factors may compromise outcomes in alloislet transplants to treat type 1 diabetes (T1D) (12, 13) . Thus, approaches to preserve beta cell mass and to reduce beta cell apoptosis after islet transplantation have potential to improve both TPIAT for surgical diabetes and islet allotransplants for T1D.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are produced by the small intestine in response to an ingested meal (14) . Although first recognized for their role in potentiating insulin secretion from beta cells, GLP-1 and GIP have been hypothesized to play a role in beta cell health (15) . In rodents, GLP-1 stimulates islet regeneration and reduces beta cell apoptosis (16) (17) (18) . In diabetic mice, pharmacologic treatment with GLP-1 analogs after marginal mass islet transplantation increases insulin independence (19, 20) . Nonrandomized trials in clinical islet allotransplantation suggest higher rates of insulin independence when the GLP-1 analog exenatide is administered, either as an initial component of the transplant regimen or later for graft dysfunction (21, 22) . However, GLP-1 analogs have significant gastrointestinal side effects, including delayed gastric emptying, nausea, and weight loss (22) (23) (24) (25) , which limit their tolerability in allotransplants and create a significant practical barrier to using them after TPIAT, where delayed gastric emptying and nausea are common (26, 27) .
GLP-1 and GIP are rapidly degraded via the enzyme dipeptidyl peptidase 4 (DPP-4) (25) . DPP-4 inhibitor therapies developed to treat type 2 diabetes increase endogenous GLP-1 and GIP levels by slowing their natural degradation by DPP-4, and these agents are better tolerated compared with GLP-1 agonists, with few gastrointestinal side effects (24) . The DPP-4 inhibitor sitagliptin increased beta cell mass in a type 2 diabetes mouse model and improved islet graft survival after transplant in streptozotocin-induced diabetic mice (28, 29) . We hypothesized that sitagliptin therapy administered immediately after TPIAT would improve islet function and insulin independence via (1) improved endogenous insulin secretion, (2) better glycemic control during islet engraftment and (3) preservation of beta cell mass by reducing beta cell apoptosis and that the latter two mechanisms would produce sustained benefit even after discontinuing therapy. To test this hypothesis, we randomized 83 nondiabetic TPIAT recipients at our institution to receive sitagliptin therapy or placebo for 12 months after TPIAT and assessed metabolic outcomes at 12 and 18 months following surgery.
Materials and Methods

Subjects
Adult patients (age ≥18 years) without preexisting diabetes mellitus who were undergoing TPIAT at the University of Minnesota between September 2010 and December 2013 were invited to participate. Before surgery, patients underwent screening tests, including fasting glucose and hemoglobin A 1c level (HbA 1c ). Patients were excluded if they had a known history of diabetes, were treated with any antihyperglycemic agents or had fasting glucose >115 mg/dL or HbA 1c >6% before TPIAT. Islet mass transplanted was obtained before randomization; patients were further excluded from randomization if transplanted islet mass was <1000 islet equivalents per kilogram body weight (IEQ/kg), below which insulin independence was considered not feasible.
Informed consent was obtained from all participants before screening. The study protocol was reviewed and approved by the Institutional Review Board at the University of Minnesota. The study protocol was reviewed by the Food and Drug Administration and determined to meet criteria for Investigational New Drug Application (IND) exemption for use in this diabetic population. The study was listed on clinicaltrials.gov (NCT01186562).
In all, 92 participants were consented and enrolled, and 83 met criteria for randomization. Participants were randomized in a 2:1 ratio to sitagliptin 100 mg daily (n = 54) or matching placebo (n = 29) ( Figure 1) ; study drug was administered starting in the evening following surgery (transplant day 0) and continued through the 12 months follow-up visit. This was followed by a 6-month washout period during which no study drug was administered from 12 to 18 months post-TPIAT. Sitagliptin and placebo were provided by the manufacturer (Merck & Co., Kenilworth, NJ) and dispensed according to the randomization schedule by the University of Minnesota investigational drug pharmacy. Participants and investigators were blinded to treatment assignment. To ensure balance, randomization was stratified by sex, BMI (< or ≥27 kg/m 2 ) and islet mass transplanted (1000-2499 IEQ/kg, 2500-4999 IEQ/kg or ≥5000 IEQ/kg).
Sample size was calculated to have an 80% power to detect an approximately twofold difference overall in insulin independence based on historical expected outcomes in each stratum of islet mass transplanted (<2500, 2500-4999, or ≥5000 IEQ/kg) and a 0.6 SD score difference in the means of any of the metabolic measures. Figure 1 : Screening, randomization, and follow-up of study population.
Surgical and islet isolation procedure
Participants underwent total or completion pancreatectomy, with pylorussparing partial duodenectomy, splenectomy, and cholecystectomy, and roux-en-Y duodenojejunostomy (2) . Care was taken to preserve blood flow to the pancreas until dissection of the pancreas was complete to avoid prolonged ischemia time. Immediately following pancreatectomy, the pancreas was taken for islet isolation. Islet isolation was performed as previously described, with enzymatic digestion with collagenase followed by mechanical disruption using the semiautomated method of Ricodi (30, 31) . COBE 2991 cell processsor (Terumo BCT, Lakewood, CO) purification was undertaken only when tissue volume was high according to our institutional protocol (generally >0.25 mL/kg) (32) . Islets were infused primarily into the portal vein of the liver, with monitoring of portal pressures and/or portal flow. If transient portal hypertension prevented infusion of all islets into the liver, then a portion of islets was transplanted elsewhere, generally into the peritoneal cavity.
Study visits and assessments
Participants were assessed before surgery and at 12 months (AE4 weeks) and 18 months (AE4 weeks) after TPIAT with HbA 1c level, mixed meal tolerance tests (MMTTs) and frequent sample intravenous glucose tolerance tests (FSIVGTTs) as described below. At both follow-up visits, insulin independence was assessed and insulin dose was calculated from 14 days of participant logs. The primary study outcome was insulin independence 12 months after TPIAT. Participants were considered insulin independent if the following criteria were met: no insulin used for >14 consecutive days, HbA 1c ≤6.5%, fasting glucose <126 mg/dL and postprandial glucoses <180 mg/dL on glucose logs. Adverse events (AEs) were assessed by telephone calls between visits and at each follow-up, and were reported if new or worsened from pretreatment baseline. Common preexisting symptoms related to the pancreatitis or TPIAT itself, including abdominal pain, nausea or vomiting, were recorded if such a symptom resolved but then recurred, the symptom had worsened from pretreatment baseline or the symptom resulted in hospital readmission (serious AE).
MMTTs were performed by administering Boost HP, 6 mL/kg, to a maximum of 360 mL; glucose and C-peptide were measured before administering the Boost HP and at 30, 60, 90 and 120 min after administration. Rarely were participants unable to perform MMTT owing to gastrointestinal complications (vomiting or limitation to jejunal feedings). Table 2 reports the participant number completing each test. From the MMTTs, area under the curve (AUC) C-peptide and glucose were calculated using the trapezoidal rule including baseline. Fasting and peak stimulated C-peptide were also derived from this test.
FSIVGTT was performed as follows: glucose, insulin and C-peptide were measured in triplicate at baseline. At time 0, a 0.3 g/kg bolus of dextrose was administered intravenously by rapid push, and at time 20 min, a 0.025 unit/kg bolus of insulin was administered, with glucose, insulin and C-peptide levels drawn at times +1, 2, 3, 4, 5, 7, 10, 12, 14, 16, 18, 20, 22, 25, 30, 40, 50, 70, 100, 140, and 180 min. The acute C-peptide response to glucose (ACRg) was calculated as the area under the curve in the first 10 min with baseline subtracted. The acute insulin response to glucose (AIRg) was similarly calculated using MinMod software (MINMOD Inc., Pasadena, CA), which was also used to compute the sensitivity index (SI) and the deposition index (DI, calculated as SI 9 AIRg, which accounts for AIRg's dependence on insulin sensitivity).
FSIVGTT was terminated early in the event of insufficient intravenous access or significant hypoglycemia (glucose <40 mg/dL or participant request).
Plasma glucose levels were measured by glucose oxidase assay, and plasma C-peptide levels were measured by Siemen's immunolite 2000 chemiluminescent immunoassay (Siemens Medical Solutions USA, Inc., Malvern, PA). Insulin levels were measured by two-site immunoenzymometric assay on a TOSOH 2000 autoanalyzer (Tosoh Bioscience, Inc., San Francisco, CA) (33, 34) . HbA 1c was analyzed by high-performance liquid chromatography.
Study compliance
In the sitagliptin group, 3 participants were lost to follow-up and 1 withdrew from outcome assessments because of pregnancy, all between TPIAT and the year 1 visit. In the placebo group, 1 participant was lost to follow-up, and 1 died following 12 months of data collection. Also, 3 participants discontinued study drug early at participant or investigator request (2 on placebo, 1 on sitagliptin) but remained in the study; and 1 additional participant in the placebo group discontinued study drug and received sitagliptin prescribed from his primary care physician. Participants were dispensed sitagliptin in 3-month supply quantities (3 bottles of 100 pills every 3 months for 12 months) and at the same time were required to return all empty bottles and remaining unused tablets to the study center. Participants were analyzed according to randomized treatment assignment (intention to treat).
All attempts were made to have participants return to the study center for follow-up. If a participant was unable to return owing to inability to travel, work or family commitments, then insulin dose, insulin independence (with HbA 1c level for validation) and adverse event history were assessed by remote visit, as indicated in Figure 1 .
Statistical analysis
Randomized groups were compared according to participant characteristics using Fisher's exact test (2-sided) for categorical outcomes and 2-sample t-tests otherwise. These outcomes were analyzed separately at each of 12 and 18 months as follows: insulin independence using Fisher's exact test (2-sided); all other insulin or metabolic outcomes, 2-sample t-test. (p-values using the Wilcoxon rank-sum test gave similar results.) Analyses of these outcomes adjusting for age, sex, BMI, and IEQ/kg used logistic regression for insulin independence and multiple linear regression for the others; results were very similar to unadjusted and are not reported.
Groups were compared according to whether individuals had any serious AEs using Fisher's exact test (2-sided). Otherwise, groups were compared according to total number of AEs of any type, total number of AEs while on study drug, number of AEs of specified types having at least 20 total AEs, and number of AEs of the same specified types while on study drug. All such analyses used Poisson regression with the aforementioned outcomes; log link; offset log (time of follow-up) or log (time on study drug) for number of AEs and number of AEs on study drug, respectively; and overdispersion correction with overdispersion estimated by Pearson's chi-squared divided by degrees of freedom. All statistical analyses were done using JMP (v. 12 Pro; SAS Institute Inc., Cary, NC).
Results
Subject characteristics
Altogether, participants had an average age of 41 (SD 11) years and BMI of 25.7 (SD 6) kg/m 2 . Putative etiologies of pancreatitis included idiopathic disease (n = 34), pancreas divisum (n = 18), sphincter of Oddi dysfunction (n = 15), genetic or familial disease (n = 11), or other precipitating factors, including alcohol or medications (n = 4). Sitagliptin-and placebo-treated participants were similar in baseline characteristics, including age, sex, BMI, IEQ/kg transplanted and baseline glycemic control and islet function (Table 1) .
Insulin independence and insulin dose
The study groups did not differ in the proportion insulin independent at 12 or 18 months. At 12 months, 42% versus 45% were insulin independent in the sitagliptin and placebo groups, respectively (p = 0.82); at 18 months, 36% versus 44%, respectively, were insulin independent (p = 0.48). To account for losses to followup, we performed sensitivity analyses assuming the "best case" for sitagliptin (all missing participants are insulin independent in the sitagliptin group and dependent in the placebo group) and "worst case" for sitagliptin (vice versa). Even with these extreme treatments of losses to follow-up, sitagliptin and placebo did not differ in insulin independence outcomes (p ≥ 0.24 for all).
Insulin dose was also similar in sitagliptin and placebo groups, with average (standard error [SE]) 9.0 (1.7) versus 7.9 (2.2) units/day, respectively, at 12 months (p = 0.67), and 10.3 (1.9) versus 7.1 (2.6) units/day, respectively, at 18 months (p = 0.32). Results were similar when adjusted for age, BMI, sex, and IEQ/kg transplanted.
Metabolic outcomes
HbA 1c did not differ significantly between the sitagliptin and placebo groups, with average (SE) 6.2% (0.1) versus 6.1% (0.2), respectively, at 12 months (p = 0.62), and 6.4% (0.2) versus 6.3% (0.3), respectively, at 18 months (p = 0.77). Response to MMTT (Figure 2 ) and insulin secretion measures from FSIVGTT were also similar at both times (Table 2 ). No differences were found after adjusting for age, sex, BMI, or IEQ/kg transplanted. In both placebo-and sitagliptin-treated groups, mean AUC C-peptide, AIRg and DI decreased over time (p < 0.0001 for all), decreasing from pre-TPIAT baseline to 12 months, with no further decrease between 12 and 18 months.
Safety
The rate of AEs during study drug treatment and during posttreatment follow-up was similar in the sitagliptin and placebo groups. For all AEs while on study drug treatment, the rate ratio was 1.01 (95% confidence interval [CI] 0.74, 1.37) for sitagliptin versus placebo; the rate ratio for serious AEs was 0.91 (95% CI 0.48, 1.70). Table 3 shows rate ratios for AEs by system. Of note, incidences of diarrhea, nausea, vomiting, abdominal pain and weight loss were no different in the sitagliptintreated participants.
Serious AEs were relatively frequent in this post-TPIAT population and most often designated unrelated or unlikely related to the study drug. Of all participants in the sitagliptin group, 57% had at least one SAE during the period of study, while 90% of placebo-treated participants had at least one SAE (p = 0.003). One placebotreated participant died after developing metastatic adenocarcinoma, diagnosed at 10 months after TPIAT and deemed unrelated to the study protocol (35) . One participant, also on placebo, also developed de novo type 1 diabetes during study follow-up (36) . Six participants experienced ≥1 severe hypoglycemia episode (1 episode each in 4 participants, and 2 episodes in 2), all related to insulin administration: three of these participants were sitagliptin-treated, and the other 3 were receiving placebo.
Discussion
Total pancreatectomy with islet autotransplantation is a valuable therapy to relieve intractable pain and restore quality of life in chronic pancreatitis (2, 3, 37, 38) . However, utilization of TPIAT remains subject to concerns about the high rate of partial diabetes after this procedure; more than half of patients require lifelong insulin therapy (2, 3) . This is likely partly due to beta cell apoptosis resulting in suboptimal engrafted beta cell mass early after TPIAT (6, 13) . On the basis of preclinical studies and data on incretin-based therapy in noncontrolled alloislet transplant trials, we randomized adult nondiabetic TPIAT patients to receive sitagliptin or placebo with standard TPIAT care. Although sitagliptin was well tolerated, it produced no substantial improvement in insulin independence, glycemic control or insulin dose in our population.
Our rationale for this randomized trial of a DPP-4 inhibitor was supported by preclinical data in murine models suggesting that both GLP-1 analogs and DPP-4 inhibitor therapy improve insulin independence following marginal mass islet transplants (28, 29, 39) . In animal models, DPP-4-and GLP-1-based therapies have been shown to reduce beta cell apoptosis, which is significantly increased after islet isolation and intraportal islet infusion (20, 40, 41) . Exenatide, a GLP-1 analog, has been administered both as a treatment for late islet graft dysfunction and as a routine component of the early posttransplant protocol, with high rates of insulin independence but without a randomized control group to adequately assess the benefits of therapy (22, 42) . However, even many allotransplant recipients were unable to tolerate exenatide owing to nausea, vomiting and weight loss, which made it a particularly impractical therapy early after TPIAT and led us instead to consider DPP-4 inhibitor therapy in this study. A more recent trial with DPP-4 inhibitor therapy in allotransplantation at the time of islet graft function (late after transplant) showed only a modest benefit in reduced insulin need, which did not persist when therapy was stopped (43) . In contrast, we observed no apparent benefit from treating TPIAT patients with sitagliptin immediately after transplant. Based on this study, there is no evidence to warrant making DPP-4 inhibitor therapy a routine component of TPIAT treatment.
The mechanisms underlying sitagliptin's failure to provide the anticipated benefit are unknown. We hypothesize that DPP-4 therapy may be insufficiently potent in humans to improve beta cell survival, particularly in adults where there is little to no capacity for beta cell replication (so that expanded islet mass would not be expected even under ideal conditions) (44) . Unlike GLP-1 agonist therapy, which delivers a pharmacologic dose of GLP-1, above that which could be achieved physiologically, sitagliptin and the other DPP-4 inhibitors increase endogenous GLP-1 and GIP levels to a high-normal physiologic range (25) . This may not suffice to provide the desired beta cell antiapoptotic and protective effect. Furthermore, GLP-1 agonists such as exenatide may benefit glycemic control through delayed gastric emptying and suppression of postprandial glucagon, beneficial effects that may not occur with DPP-4 inhibitor therapy (45) . Other studies have combined sitagliptin therapy with a proton-pump inhibitor (PPI) to increase gastrin levels, targeting a synergistic effect of GLP-1 with gastrin for beta cell replication (43, 46) , Although our study protocol did not include a specific PPI, our routine clinical management protocol for TPIAT patients includes PPI therapy immediately after TPIAT and most often continues it for 1 year or more.
Second, gastrointestinal anatomy is altered following TPIAT, which may have affected either the absorption or the incretin response to sitagliptin therapy in our population. These patients have, by definition, pancreatic exocrine insufficiency and may have variable malabsorption that could affect drug absorption. Furthermore, a portion of the duodenum, which contains enteroendocrine cells that produce GLP-1 and GIP, is removed, and ingested nutrients are delivered directly to the jejunum (47) . Therefore, the "normal" incretin response may be altered and thus differently affected by sitagliptin treatment. Future analysis of postprandial GLP-1 and GIP levels in this population may help clarify whether, in fact, sitagliptin therapy achieved its intended pharmacologic effect of increasing endogenous GLP-1 and GIP.
Of note, although not statistically significant, there was a small rise in insulin dependence and insulin dose between 12 and 18 months in the sitagliptin group, whereas insulin use in the placebo group was unchanged. One could postulate that there may be a small effect of the sitagliptin treatment on insulin requirements or that there is an accelerated beta cell failure after withdrawal of sitagliptin similar to that proposed with sulfonylurea treatment in type 2 diabetes (48) . It is also possible that the study is not powered enough to detect small differences in insulin independence. The feasibility of conducting any larger trial in the small population of adult islet autograft recipients is limited, however, and the nearly identical metabolic profiles of our sitagliptin-and placebo-treated participants certainly suggests that no substantial benefit exists, even if more participants were studied.
In conclusion, our study does not support routine use of DPP-4 inhibitor therapy after TPIAT for chronic pancreatitis. Although this finding may temper enthusiasm for these same agents in islet allotransplantation for type 1 diabetes, these findings may or may not directly extrapolate to that patient population.
